Margetuximab Plus Chemo Improves PFS in HER2-Positive, Metastatic Breast Cancer

Hope S. Rugo, MD, University of California San Francisco Comprehensive Cancer Center, discusses the clinical significance and findings of the phase 3 SOPHIA clinical trial.